A Study to Assess Safety, Tolerability, and Efficacy of HTL0018318 in Patients With Dementia With Lewy Bodies

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

PHASE2

Study Classification

INTERVENTIONAL

Study Start Date

2019-07-31

Study Completion Date

2021-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To establish the safety and efficacy of HTL0018318 compared with placebo when administered once daily for 12 weeks to patients with dementia with Lewy bodies.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study to Evaluate the Safety, Tolerability and Efficacy of CT1812 in Subjects With Mild to Moderate Dementia With Lewy Bodies

NCT05225415

Dementia With Lewy Bodies

COMPLETED PHASE2

K0706 for Patients Diagnosed With Dementia With Lewy Bodies

NCT03996460

Dementia With Lewy Bodies

RECRUITING PHASE2

A Phase I, Single Dose Study Of PF-04360365 In Japanese Patients With Mild To Moderate Alzheimer's Disease

NCT00607308

Alzheimer's Disease

COMPLETED PHASE1

A Multiple Ascending Dose Study in Healthy Volunteers and Patients With Alzheimer's Disease

NCT05804383

Alzheimer's Disease

COMPLETED PHASE1

Multi-centre Study of HTL0018318 in Patients as an add-on to Standard-of-care

NCT03456349

Alzheimer's Disease

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

To assess the safety, tolerability and efficacy of HTL0018318 at 3 dose levels (once daily) compared with placebo over a 12-week treatment period in patients with dementia with Lewy bodies (DLB). Approximately 140 DLB patients who have not received donepezil (Aricept®) and/or other acetyl cholinesterase inhibitors (AchEi) and approximately 32 DLB patients who have had prior treatment experience with donepezil but have stopped usage will be enrolled.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Dementia With Lewy Bodies

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Placebo controlled

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Double blind

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

HTL0018318 high dose

oral capsule, once daily

Group Type EXPERIMENTAL

HTL0018318

Intervention Type DRUG

Oral capsule

HTL0018318 mid dose

oral capsule, once daily

Group Type EXPERIMENTAL

HTL0018318

Intervention Type DRUG

Oral capsule

HTL0018318 low dose

oral capsule, once daily

Group Type EXPERIMENTAL

HTL0018318

Intervention Type DRUG

Oral capsule

Placebo

oral capsule, once daily

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Oral capsule

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

HTL0018318

Oral capsule

Intervention Type DRUG

Placebo

Oral capsule

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosed with probable DLB according to the fourth revision of consensus diagnostic criteria for DLB.
* Clinical imaging evidence from either SPECT or MIBG cardiac scintigraphy that is consistent with a clinical diagnosis of DLB.
* Partner or caregiver able to support the patient for the duration of the clinical trial.

Exclusion Criteria

* Patients with a diagnosis of Parkinson disease at least 1 year prior to onset of dementia.
* Patients with the presence of severe extrapyramidal symptoms
* Patients with the presence of an illness/condition apart from DLB that could contribute to cognitive dysfunction
* Patients with poorly controlled hypertension despite lifestyle modifications and/or pharmacotherapy, who are currently on more than 2 different antihypertensive treatments
* Patients with prominent, recurrent episodes of syncope are related to orthostatic hypotension
* Patients with pulmonary disease or evidence of clinically significant moderate or severe pulmonary symptoms
* Patients who are taking a range of prohibited and restricted medication
* Patients who have been prescribed individualised cognitive rehabilitation, stimulation or training that was performed under medical supervision in the 6 months prior to the screening visit
* Patients who have any known condition(s) that may be contraindicated or interfere with the completion of the nuclear imaging scans.

Minimum Eligible Age

50 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No